$CMPS News Article - COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
https://marketwirenews.com/news-releases/comp...36233.html